Abstract:Immune checkpoint inhibitors (ICIs) have become an important treatment modality for various malignancies. Due to excessive inflammatory and immune responses, immune-related adverse events (irAEs), such as rash, pruritis, pneumonitis, hepatitis, hypothyroidism, hyperthyroidism and fatigue, can occur. Acquired immune thrombocytopenia is a rare irAE that can lead to severe low platelet counts and hemorrhage. A retrospective observational analysis was conducted on data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS). We searched for all reports recorded in the FAERS covering the period from 2011 Q1 to 2023 Q4 for target agents. Signal analysis was performed using the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN) and multi-item gamma Poisson shrinker (MGPS) algorithm. Nonparametric tests were used to compare the time to onset of thrombocytopenia-associated fractures between different regimens. There were 404 reports of immune thrombocytopenia in the FAERS database. Immune thrombocytopenia was associated with all ICIs except tremelimumab, and signals were detected by all 4 methods. The median time to the onset of immune thrombocytopenia caused by PD-1, PD-L1 and CTLA-4 inhibitors was 47 days (range: 21-139.2), 21 days (range: 13–131) and 9 days (range: 7–27), respectively. The Weibull shape parameter test revealed that pembrolizumab-, durvalumab-, and ipilimumab-induced thrombocytopenia had a random failure-type profile, and nivolumab- and atezolizumab-induced thrombocytopenia were characterized by an early failure-type profile. There was a significant reporting signal of ICI-induced thrombocytopenia associated with most ICIs. Immune thrombocytopenia has a greater incidence in males, elderly individuals and Asian populations, and PD-1 inhibitors were the most common cause. Clinicians should be aware of the signs of potential serious adverse events.

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors

High Incidence of Venous Thromboembolism Due to Immune Checkpoint Inhibitors:an Immunotherapy-related Toxicity

Cardiovascular and venous thromboembolism risks in cancer patients treated with immune checkpoint inhibitors compared to non-users- a multi-center retrospective study

[Incidence and Risk Factors of Thromboembolism in Patients with Lung Cancer Receiving Immunotherapy].

Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers

Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy

Advances in Immune Checkpoint Inhibitors Induced-Cardiotoxicity

Toxicity of tumor immune checkpoint inhibitors-more attention should be paid.

Thrombotic Events Associated with Immune Checkpoint Inhibitors and Novel Antithrombotic Strategies to Mitigate Bleeding Risk.

Incidence of thromboembolic events in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Update on Thrombosis Risk in Patients with Cancer: Focus on Novel Anticancer Immunotherapies

Incidence, Morphology and Clinical Relevance of Bony Canals and Vascular Grooves in the Paracondylar Region of Adult Human Skulls

Risk Factors for Immune-Related Adverse Events: What Have We Learned and What Lies Ahead?

Thromboembolism during immune checkpoint inhibitor therapy: frequency and risk factors

Risk factors for cardiovascular adverse events from immune checkpoint inhibitors

Biomarkers and risk factors for the early prediction of immune-related adverse events: a review.

Rheumatic complications in cancer patients treated with immune checkpoint inhibitors

Signal detection of immune thrombocytopenia associated with immune checkpoint inhibitors

Immune-related Adverse Events of Immune Checkpoint Inhibitors: a Review

Delayed thrombocytopenia as a rare but serious adverse event secondary to immune checkpoint inhibitor: a case report.